TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03484221
Drug: XELOX
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OXALIPLATIN 130 mg/m\^2 IV over 2-h, day 1 Capecitabine 1000 mg/m\^2 twice daily days 1-14 every 3 weeks for 4 cycles.
Study: NCT00829816
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03688958
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selected patients with early breast cancer (stage II) non-pretreated received colored water solution (placebo) within the time before the hospital assigned them to her surgery (7 to 35 days).
Study: NCT02271906
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
Study: NCT01953835
Drug: GSK2586184 standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet. For cohort A, it is to be administered at 400 mg (200 mg x 2 tablets) twice daily from Day 6 to Day 14. For cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose after standard breakfast either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day wash out period.
Study: NCT01953835
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 10 mg oral tablet is peach-coloured, oval-shaped tablets. It is to be administered orally as a single dose of 10 mg tablet on the mornings of Day 1 and Day 10.
Study: NCT01953835
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
Study: NCT01953835
Drug: GSK2586184 new formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
Study: NCT04314206
Drug: Placebo for VNRX-5024
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part 1: one dose~Part 2:~Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours \[q12h\] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours \[q8h\] dosing for 9 days with a single morning dose on Day 10)
Study: NCT03193658
Drug: I.V drug based multimodal approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: A base low dose opioid of 5mg morphine I.V every 8 hours. Rescue analgesia will be given to the patient if reported a VAS equal or more than 4 in the form of I.V morphine in 2.5mg increments till VAS returns to 4 or less in addition to 1 gm of oral acetaminophen every 6 hours
Study: NCT01921985
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
Study: NCT02560324
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04182568
Drug: nab-paclitaxel followed by anthracycline and cyclophosphamide
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: nab-paclitaxel 260mg/m2 for every 2 weeks followed by anthracycline and cyclophosphamide
Study: NCT04182568
Drug: Docetaxel followed by anthracycline and cyclophosphamide
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 100 mg/m2 for for every 2 weeks followed by anthracycline and cyclophosphamide
Study: NCT00501059
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken daily
Study: NCT00270231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.~Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule.
Study: NCT01147757
Drug: remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: During surgery, 3 different dose of remifentanil or placebo was infused.
Study: NCT02710669
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00511316
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 20 mg daily for 6 months
Study: NCT00091637
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: bolus infusion over a 10 minute period once
Study: NCT01746238
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks
Study: NCT03433313
Drug: EG12014
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG12014 6mg/kg is ongoing to be administered after 8mg/kg loading dose.
Study: NCT00069784
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo gelatin capsules (containing olive oil) for oral administration
Study: NCT02512679
Drug: Cyclophosphamide Dose Level 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met.
Study: NCT02512679
Drug: Cyclophosphamide Dose Level 2
Normalized name: cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Level 2 will be 70mg/kg in 2 divided given once a day for 2 days;
Study: NCT02512679
Drug: Cyclophosphamide Dose Level 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 3 will be 35mg/kg as a one-time dose.
Study: NCT02512679
Drug: Cyclophosphamide Dose Level 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Level 4 will be no cytoxan.
Study: NCT02063100
Drug: Shenyankangfu tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.
Study: NCT03660475
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ophthalmic solution
Study: NCT02535130
Drug: amikacine nebulization
Normalized name: Amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00432276
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo tablets.
Study: NCT00297115
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily
Study: NCT00959062
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation visually identical to clonidine.
Study: NCT02334553
Drug: S1226(8%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
Study: NCT02334553
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
Study: NCT01528943
Drug: Prostacycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min
Study: NCT01528943
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: same volume as the group that are allocated to prostacycline
Study: NCT02755064
Drug: Placebo IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Phase 1 of the study, during the second visit, saline was given as an initial bolus over 10 min immediately before the meal. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
Study: NCT02755064
Drug: [13C]-Spirulina
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
Study: NCT02755064
Drug: Placebo Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days.
Study: NCT03140956
Drug: Levodopa, carbidopa, ODM-104
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover design. Study treatments will be administered in randomized order 4 times a day.
Study: NCT01128218
Drug: Tumor fluorescence
Normalized name: human breast tumor cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg.~Recommended oral dose of phase 1 will be used in phase 2
Study: NCT04030962
Drug: AGN-242428
Normalized name: VITEX AGNUS-CASTUS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ophthalmic solution administered as a topical eye drop
Study: NCT01984489
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02590874
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.
Study: NCT01523184
Drug: Placebo Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is the placebo capsule
Study: NCT01523184
Drug: YKP10811 Drug Product Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug product, YKP10811, 10 mg under investigation
Study: NCT01523184
Drug: YKP10811 Drug Product Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug product, YKP10811, 20 mg under investigation
Study: NCT01523184
Drug: YKP10811 Drug Product Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug product, YKP10811, 30 mg under investigation
Study: NCT03962296
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets lacked Vitis vinifera extract or calcium dobesilate, but their appearance was identical to those of the study group tablets.
Study: NCT02000830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered by IM injection
Study: NCT02737228
Drug: CG200745 PPA
Approvals — FDA: no, EMA: no, PMDA: no
Description: CG200745 PPA IV every week three times per cycle (4 weeks)
Study: NCT02277158
Drug: Chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 CCRT
Study: NCT01966419
Drug: ornithine phenylacetate
Normalized name: phenylacetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ornithine phenylacetate for continuous IV infusion at dose levels predicated on level of hepatic decompensation
Study: NCT04500496
Drug: dinoprostone
Normalized name: Dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the patient 12 hours before the scheduled office hysteroscopy.
Study: NCT01966419
Drug: placebo intravenous infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for continuous IV infusion that is visually identical to the experimental product
Study: NCT02962323
Drug: Torrent's Rosuvastatin Calcium Tablets 40 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, crossover
Study: NCT02962323
Drug: Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral, crossover
Study: NCT01264380
Drug: RO5185426
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose, fasted
Study: NCT01264380
Drug: RO5185426
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose, with high fat meal
Study: NCT01264380
Drug: RO5185426
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous administration, orally twice daily
Study: NCT00240955
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02563002
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen consists of oxaliplatin 85 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
Study: NCT02563002
Drug: FOLFIRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen consists of irinotecan 180 mg/m\^2 IV on Day 1, leucovorin 400 mg/m\^2 or levoleucovorin 200 mg/m\^2 IV on Day 1, 5-FU 400 mg/m\^2 IV bolus on Day 1 and then 1200 mg/m\^2/day IV over 2 days for total dose of 2400 mg/m\^2 in each 2-week cycle
Study: NCT03240224
Drug: Life information rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Study: NCT02466646
Drug: Klorhex® Gel, rinse and spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Spray 0,2% and Klorhex® rinse 0,2% for 3 weeks).
Study: NCT02768610
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02401464
Drug: TAK-536 Dry Syrup Formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-536 dry syrup formulation
Study: NCT02401464
Drug: TAK-536 Ganule Formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-536 granule formulation
Study: NCT00886028
Drug: Liposomal doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal doxorubicin 60 mg/m2 every 4 weeks for 6 cycles.~Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
Study: NCT03270514
Drug: Exparel Injectable Product
Normalized name: Exparel Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
Study: NCT00624559
Drug: celecoxib (Celebrex)
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
Study: NCT03620422
Drug: Salbutamol 5mg/mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized salbutamol given prior to Mannitol-Induced Cough Challenge
Study: NCT02801669
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally administered once daily.
Study: NCT01444365
Drug: ABT-652 NSAID
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed
Study: NCT02295566
Drug: Nitric Oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Not required
Study: NCT01444365
Drug: Placebo NSAID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo - 2 placebo capsules twice daily NSAID- as prescribed
Study: NCT01363128
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01363128
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01363128
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00680134
Drug: AN2690
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
Study: NCT00016042
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02271399
Drug: acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.
Study: NCT04492150
Drug: Dextrose 5%/Nacl 0.3% Inj_#3
Normalized name: DEXTROSE 5%/NACL 0.3% INJ_#3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL/hour of dextrose 5% intravenous drip
Study: NCT00003305
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01555190
Drug: myo-inositol 1500 gr
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01555190
Drug: myo-inositol 2000 gr + folic acid 200 mcg
Normalized name: myo-inositol
DrugBank: Inositol (DB13178)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04492319
Drug: Control Test
Normalized name: CHEK-STIX URINALYSIS CONTROL TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: spermatic cord block by 19 ml Levobupivacaine 0.5% plus 1 ml 0.9 normal saline in each side
Study: NCT05691764
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous placebo
Study: NCT00894790
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
Study: NCT00894790
Drug: oral Diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac 75 mg tablet BID (twice a day)
Study: NCT01046032
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
Study: NCT01287520
Drug: LY2090314
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously
Study: NCT02675790
Drug: Moderate Dose Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.
Study: NCT02675790
Drug: Low Dose Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.
Study: NCT04482595
Drug: BIO 300 Oral Suspension
Normalized name: Bio-Kool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suspension of genistein nanoparticles
Study: NCT04482595
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo for BIO 300 Oral Suspension
Study: NCT03432884
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive Placebo
Study: NCT03802565
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03430661
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching ACT-246475 placebo will consist of sterile 0.9% w/v sodium chloride solution
Study: NCT00672841
Drug: Empiric antifungal therapy based on physician discretion.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the standard care group may receive antifungal prophylaxis and/or treatment at any time based on the discretion of the treating physician.
Study: NCT04779606
Drug: Ocular gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 drops instilled in the right eye
Study: NCT03938649
Drug: SBRT
Normalized name: Stereotactic Body Radiation Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: RapidArc IMRT to prostate and pelvic nodes. 40Gy to prostate, 36.25Gy to proximal 2/3 of seminal vesicles, and 25Gy to pelvic nodes (up to bifurcation of common iliac nodes) 5 fractions of weekly treatment. Once fraction per week. All patients will be given neoadjuvant and adjuvant androgen deprivation therapy.
Study: NCT02624388
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill that contains no medicine
Study: NCT00875433
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients to receive continuous oral daily dosing of BIBW 2992
Study: NCT00790127
Drug: HQK-1001
Approvals — FDA: no, EMA: no, PMDA: no
Description: HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days
Study: NCT00790127
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules administered once a day, orally, for 56 days
Study: NCT01167049
Drug: CAPECITABINE
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);
Study: NCT00637806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral suspension, 5 mL once daily
Study: NCT00561470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
Study: NCT01991821
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00568087
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will take oral placebo (identical matching placebo) during the study period.